BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . 81% (88/109) of patients achieved remission * with BESPONSA compared to 29% (32/109) of patients with chemotherapy * Remission means that no leukemia cells can be seen when looking at bone marrow under a microscope.. Modify the dose of BESPONSA for toxicities (see Tables 2-4). BESPONSA doses within a treatment BESPONSA doses within a treatment cycle (i.e., Days 8 and/or 15) do not need to be interrupted due to neutropenia or thrombocytopenia, but.